---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-028128"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2022-11-29T23:59:59+00:00"
generated_at: "2026-06-21T12:12:33.613234+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# KemPharm appoints Christopher A. Posner to board of directors

## Summary
- Christopher A. Posner appointed effective November 28, 2022 as Class II director with term expiring at 2023 annual meeting.
- Posner is President and CEO of Cara Therapeutics; brings experience in pharmaceutical commercial operations and product management.
- Received initial option grant for 22,500 shares vesting over three years; annual cash retainer of $40,000 under non-employee director policy.
- Eligible for additional annual option grant of 15,000 shares at each subsequent annual meeting where term continues.

## SEC filing metadata
- accession: 0001437749-22-028128
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2022-11-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774922028128/0001437749-22-028128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774922028128/kmph20221128_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-028128
- JSON: https://secwatch.observer/filing/0001437749-22-028128.json
- Plain text: https://secwatch.observer/filing/0001437749-22-028128.txt

## Key facts
- Executive change
  Christopher A. Posner was appointed as Director at ZEVRA THERAPEUTICS, INC..
  - Action: appointed
  - Role: Director
  source text: On November 28, 2022, the board of directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Christopher A. Posner to serve as a director of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434647/000143774922028128/0001437749-22-028128-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.